Comparative Pharmacology
Head-to-head clinical analysis: GALLIUM GA 68 EDOTREOTIDE versus MACROTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GALLIUM GA 68 EDOTREOTIDE versus MACROTEC.
GALLIUM GA 68 EDOTREOTIDE vs MACROTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gallium Ga 68 edotreotide is a radiopharmaceutical analog of somatostatin that binds to somatostatin receptors, particularly subtype 2 (SSTR2), which are overexpressed on neuroendocrine tumor cells. After binding, internalization occurs, and the gallium-68 isotope emits positrons for PET imaging.
Not applicable for diagnostic use.
148-259 MBq (4-7 mCi) IV once for PET imaging.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
None Documented
None Documented
Terminal elimination half-life: 0.5–2.5 hours (mean 1.2 hours); clinically allows same-day imaging after injection.
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
Renal: >90% unchanged in urine within 24 hours; biliary/fecal: <2%.
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical